Test Price
2,800 AED✅ Home Collection Available
PEX3 Gene Peroxisome Biogenesis Disorder Type 10A Genetic Test in Dubai, UAE
Executive Summary & Core Metrics
Precision Molecular Diagnostics for Peroxisomal Disorders
- ● Diagnostic Accuracy: 99.9% clinical sensitivity and specificity validated through ISO 9001:2015 accredited next-generation sequencing (NGS) with full PEX3 gene coverage.
- ● Home Collection Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM to 11 PM, with ISO‑certified transport.
- ● Post‑Test Guidance: Dedicated telephonic clinical interpretation session with our Consultant Medical Genetics specialist.
- ● Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The PEX3 gene NGS test detects pathogenic variants associated with peroxisome biogenesis disorder type 10A (Zellweger spectrum). Utilizing next-generation sequencing, the assay delivers comprehensive molecular diagnosis for neurodevelopmental and metabolic disorders, enabling targeted clinical management through precise genotyping.
The test sequences all coding exons and flanking intronic regions of the PEX3 gene with a minimum depth of 100×, ensuring detection of single-nucleotide variants, insertions, deletions, and copy-number alterations. Bioinformatic analysis employs validated pipelines for variant calling and classification per ACMG guidelines.
| Feature | DNA Labs UAE PEX3 Test | Conventional Alternatives |
|---|---|---|
| Detection Rate | >99.9% across all variant types with full gene coverage | Limited to targeted hotspot regions; missense detection rates below 85% |
| Platform | Illumina NGS with orthogonal Sanger confirmation | Single-gene Sanger or limited panel by PCR |
| Turnaround Time | 21–28 business days inclusive of clinical interpretation | Often 6–10 weeks without formal interpretation |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I recognise that pursuing a diagnosis for peroxisomal biogenesis disorders can be a prolonged and emotionally demanding journey. This targeted NGS assay provides definitive molecular answers that can transform clinical care. I urge families to pair genetic results with biochemical profiling and neurological evaluation for comprehensive management. Our team is here to support you with clear, compassionate guidance through every stage of testing.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication Continuity & Clinical Supervision
⚠️ Important Clinical Advisory
Never discontinue or adjust prescribed medications — including anticonvulsants, metabolic therapies, or supportive agents — without explicit guidance from the treating physician. Abrupt changes may precipitate metabolic crises or neurological deterioration.
Exclusion Criteria & Emergency Red Flags
Contraindications & Urgent Symptoms
- Exclusion: This test is not indicated as a population screening tool or for asymptomatic individuals without clinical or biochemical evidence of peroxisomal dysfunction. Specimens with severely degraded DNA or insufficient quantity may be rejected.
- Emergency Red Flags: Acute neurological decline, new-onset seizures, unexplained loss of consciousness, or signs of severe metabolic acidosis (e.g., vomiting, lethargy, tachypnea) require immediate emergency medical attention. Do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. What is the PEX3 gene test and why is it clinically relevant?
The test sequences the entire PEX3 coding region to identify pathogenic mutations that cause peroxisome biogenesis disorder type 10A (Zellweger spectrum). Accurate molecular diagnosis guides prognosis, informs reproductive planning, and enables tailored metabolic and neurological management.
2. How is the specimen collected and what is the expected turnaround time?
A peripheral blood sample (3–5 mL in EDTA tube) or a DNA FTA card is collected via VIP Mobile Phlebotomy at your home. Results are reported within 21–28 business days, inclusive of comprehensive bioinformatic analysis and clinical interpretation.
3. Can this test be performed on paediatric patients and what are the associated risks?
Yes, the test is suitable for children of all ages with informed parental or guardian consent. The procedure carries minimal risks — limited to standard venipuncture discomfort, occasional bruising, and a very low probability of infection. No sedation is required.
UAE Regulatory & Data Privacy Adherence
Compliance & Certification
All diagnostic processes conform to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Licensed Medical Facility No. 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | All tests are processed in a CAP‑accredited laboratory.
Clinical & Logistical Metadata
| Test Name | PEX3 Gene Peroxisome Biogenesis Disorder Type 10A NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Business Days (3–4 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or DNA FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) with Bioinformatic Validation & Sanger Confirmation |
| ICD-10-CM Code | E71.518 (Other peroxisome biogenesis disorders) |
| LOINC Code | 102006-9 (Peroxisomal biogenesis disorder gene panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians